Cell Therapy Limited has been rebranded to Celixir Limited reflecting its mission to discover, develop and deliver life-saving and life-altering medicines to patients in need.
CARDIFF 20 July, 2016 – Celixir, a leading British biotechnology company delivering breakthrough regenerative medicines, has today rebranded from Cell Therapy. The change reflects the company’s continued commitment to discovering, developing and delivering life-altering regenerative medicines, and transforming patient care.
“The name Celixir combines ‘Cell’ with the Latin root word elixir to convey our vision to develop curative regenerative medicines”, said Ajan Reginald, Chief Executive Officer of Celixir. “Adopting the Celixir name signals the company’s evolution with an expanded portfolio of medicines, international partnerships and robust financial position. It’s a fitting way to mark our 7th anniversary”.
To coincide with the rebrand, Celixir has unveiled a new logo and website https://www.celixir.com. The new site offers the latest information about the company’s platform technology, product portfolio, clinical evidence and stellar leadership, in an easy-to-use format.
The rebrand is effective immediately and will be implemented across all of the company’s platforms and all future communications.
Celixir (formerly known as Cell Therapy Limited) is a private British regenerative medicine company that discovers and develops life-saving and life-altering regenerative medicines for patients with the greatest medical need. Celixir, founded in 2009, is made up of a world-class team of scientists and biopharmaceutical executives, led by Nobel Laureate Professor Sir Martin Evans and former Roche Global Head of Emerging Technologies, Ajan Reginald. Celixir’s unique platform technology allows them to adopt an ‘off-the-shelf’ approach to deliver regenerative medicines to patients.